MedKoo Cat#: 562898 | Name: Alvimopan Dihydrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alvimopan Dihydrate is a peripherally acting μ opioid antagonist.

Chemical Structure

Alvimopan Dihydrate
Alvimopan Dihydrate
CAS#170098-38-1 (dihydrate)

Theoretical Analysis

MedKoo Cat#: 562898

Name: Alvimopan Dihydrate

CAS#: 170098-38-1 (dihydrate)

Chemical Formula: C25H36N2O6

Exact Mass: 460.2573

Molecular Weight: 460.57

Elemental Analysis: C, 65.20; H, 7.88; N, 6.08; O, 20.84

Price and Availability

Size Price Availability Quantity
10mg USD 425.00 2 Weeks
50mg USD 985.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Alvimopan Dihydrate; Entereg; Alvimopan hydrate; LY 246736 dihydrate; LY-246736 dihydrate; LY246736 dihydrate;
IUPAC/Chemical Name
2-[[(2S)-2-Benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid;dihydrate
InChi Key
USPVLEIQIUNQGE-DBFLIVQGSA-N
InChi Code
InChI=1S/C25H32N2O4.2H2O/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19;;/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30);2*1H2/t18-,20-,25+;;/m0../s1
SMILES Code
O=C(O)CNC([C@@H](CC1=CC=CC=C1)CN2C[C@H](C)[C@](C)(C3=CC=CC(O)=C3)CC2)=O.[H]O[H].[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 460.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kranz J, Krabbe LM. [Alvimopan for recovery of bowel function after radical cystectomy]. Urologe A. 2018 Feb;57(2):207-210. doi: 10.1007/s00120-018-0579-5. Review. German. PubMed PMID: 29396627. 2: Nee J, Zakari M, Sugarman MA, Whelan J, Hirsch W, Sultan S, Ballou S, Iturrino J, Lembo A. Efficacy of Treatments for Opioid-induced Constipation: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2018 Jan 25. pii: S1542-3565(18)30087-9. doi: 10.1016/j.cgh.2018.01.021. [Epub ahead of print] Review. PubMed PMID: 29374616. 3: Sridharan K, Sivaramakrishnan G. Drugs for Treating Opioid-Induced Constipation: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials. J Pain Symptom Manage. 2018 Feb;55(2):468-479.e1. doi: 10.1016/j.jpainsymman.2017.08.022. Epub 2017 Sep 15. Review. Erratum in: J Pain Symptom Manage. 2018 Mar;55(3):e11. PubMed PMID: 28919541. 4: Sultan S, Coles B, Dahm P. Alvimopan for recovery of bowel function after radical cystectomy. Cochrane Database Syst Rev. 2017 May 2;5:CD012111. doi: 10.1002/14651858.CD012111.pub2. Review. PubMed PMID: 28462518. 5: Pergolizzi JV Jr, Raffa RB, Pappagallo M, Fleischer C, Pergolizzi J 3rd, Zampogna G, Duval E, Hishmeh J, LeQuang JA, Taylor R Jr. Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient Prefer Adherence. 2017 Jan 17;11:107-119. doi: 10.2147/PPA.S78042. eCollection 2017. Review. PubMed PMID: 28176913; PubMed Central PMCID: PMC5261842. 6: Xu LL, Zhou XQ, Yi PS, Zhang M, Li J, Xu MQ. Alvimopan combined with enhanced recovery strategy for managing postoperative ileus after open abdominal surgery: a systematic review and meta-analysis. J Surg Res. 2016 Jun 1;203(1):211-21. doi: 10.1016/j.jss.2016.01.027. Epub 2016 Feb 23. Review. PubMed PMID: 27338552. 7: Drake TM, Ward AE. Pharmacological management to prevent ileus in major abdominal surgery: a systematic review and meta-analysis. J Gastrointest Surg. 2016 Jun;20(6):1253-64. doi: 10.1007/s11605-016-3140-0. Epub 2016 Apr 12. Review. PubMed PMID: 27073081. 8: Cui Y, Chen H, Qi L, Zu X, Li Y. Effect of alvimopan on accelerates gastrointestinal recovery after radical cystectomy: A systematic review and meta-analysis. Int J Surg. 2016 Jan;25:1-6. doi: 10.1016/j.ijsu.2015.11.013. Epub 2015 Nov 18. Review. PubMed PMID: 26596716. 9: Brady JT, Dosokey EM, Crawshaw BP, Steele SR, Delaney CP. The use of alvimopan for postoperative ileus in small and large bowel resections. Expert Rev Gastroenterol Hepatol. 2015;9(11):1351-8. doi: 10.1586/17474124.2015.1095637. Epub 2015 Oct 21. Review. PubMed PMID: 26488223. 10: Davis M, Gamier P. New Options in Constipation Management. Curr Oncol Rep. 2015 Dec;17(12):55. doi: 10.1007/s11912-015-0481-x. Review. PubMed PMID: 26449843. 11: Ahmedzai SH, Boland JW. Constipation: opioid antagonists in people prescribed opioids. BMJ Clin Evid. 2015 Sep 11;2015. pii: 2407. Review. PubMed PMID: 26360669; PubMed Central PMCID: PMC4566814. 12: Berger NG, Ridolfi TJ, Ludwig KA. Delayed gastrointestinal recovery after abdominal operation - role of alvimopan. Clin Exp Gastroenterol. 2015 Aug 5;8:231-5. doi: 10.2147/CEG.S64029. eCollection 2015. Review. PubMed PMID: 26346889; PubMed Central PMCID: PMC4531031. 13: Johnson DC, Greene PS, Nielsen ME. Surgical advances in bladder cancer: at what cost? Urol Clin North Am. 2015 May;42(2):235-52, ix. doi: 10.1016/j.ucl.2015.01.005. Epub 2015 Mar 3. Review. PubMed PMID: 25882565. 14: Bragg D, El-Sharkawy AM, Psaltis E, Maxwell-Armstrong CA, Lobo DN. Postoperative ileus: Recent developments in pathophysiology and management. Clin Nutr. 2015 Jun;34(3):367-76. doi: 10.1016/j.clnu.2015.01.016. Epub 2015 Jan 31. Review. PubMed PMID: 25819420. 15: Siemens W, Gaertner J, Becker G. Advances in pharmacotherapy for opioid-induced constipation - a systematic review. Expert Opin Pharmacother. 2015 Mar;16(4):515-32. doi: 10.1517/14656566.2015.995625. Epub 2014 Dec 24. Review. PubMed PMID: 25539282. 16: Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014 Sep 19;7:345-58. doi: 10.2147/CEG.S52097. eCollection 2014. Review. PubMed PMID: 25278772; PubMed Central PMCID: PMC4179399. 17: Carroll FI, Dolle RE. The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists. ChemMedChem. 2014 Aug;9(8):1638-54. doi: 10.1002/cmdc.201402142. Epub 2014 Jun 30. Review. PubMed PMID: 24981721; PubMed Central PMCID: PMC5588862. 18: Keller D, Stein SL. Facilitating return of bowel function after colorectal surgery: alvimopan and gum chewing. Clin Colon Rectal Surg. 2013 Sep;26(3):186-90. doi: 10.1055/s-0033-1351137. Review. PubMed PMID: 24436673; PubMed Central PMCID: PMC3747279. 19: Richards KA, Steinberg GD. Perioperative outcomes in radical cystectomy: how to reduce morbidity? Curr Opin Urol. 2013 Sep;23(5):456-65. doi: 10.1097/MOU.0b013e32836392bb. Review. PubMed PMID: 23907504. 20: Sharma A, Jamal MM. Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies. Curr Gastroenterol Rep. 2013 Jul;15(7):334. doi: 10.1007/s11894-013-0334-4. Review. PubMed PMID: 23836088.